Regeneron Pharmaceuticals will release its fourth-quarter earnings later this month, and analysts anticipate a double-digit ...

The going has been strong for Regeneron Pharmaceuticals REGN over the past six months. Shares of this biotech giant have ...

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...

Regeneron Pharmaceuticals, a company that has been analyzing genetic data as part of its drug research for more than a decade, is augmenting its capabilities in a big way with the $256 million ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S.

The genetic medicines field is working toward therapies capable of doing their editing work inside the body by reaching many different types of tissue and cell types. Regeneron Pharmaceuticals and ...

The Thursday morning update indicates Regeneron Pharmaceuticals shares down by 0.27%, currently priced at $771.87. At this value, Sing's 9,212 shares are worth $2,320,134.

NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.

Chief District Judge Thomas Kleeh denied Regeneron Pharmaceuticals, Inc.‘s (NASDAQ:REGN) effort to prevent the sale of Amgen Inc‘s (NASDAQ:AMGN) Eylea biosimilar. Regeneron filed a notice of its ...

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:REGN), and it's something market players shouldn't ignore. Our tracking of public options records at ...